98 related articles for article (PubMed ID: 17208922)
1. Image-based screening for the identification of novel proteasome inhibitors.
Rickardson L; Wickström M; Larsson R; Lövborg H
J Biomol Screen; 2007 Mar; 12(2):203-10. PubMed ID: 17208922
[TBL] [Abstract][Full Text] [Related]
2. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
3. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
4. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors.
Williams RG; Kandasamy R; Nickischer D; Trask OJ; Laethem C; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():364-89. PubMed ID: 17110203
[TBL] [Abstract][Full Text] [Related]
7. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
8. Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform.
Trask OJ; Baker A; Williams RG; Nickischer D; Kandasamy R; Laethem C; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():419-39. PubMed ID: 17110205
[TBL] [Abstract][Full Text] [Related]
9. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
[TBL] [Abstract][Full Text] [Related]
10. BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
Sterz J; Jakob C; Kuckelkorn U; Heider U; Mieth M; Kleeberg L; Kaiser M; Kloetzel PM; Sezer O; von Metzler I
Eur J Haematol; 2010 Aug; 85(2):99-107. PubMed ID: 20374272
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
12. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacodynamic imaging of proteasome inhibition.
Kimbrel EA; Davis TN; Bradner JE; Kung AL
Mol Imaging; 2009; 8(3):140-7. PubMed ID: 19723471
[TBL] [Abstract][Full Text] [Related]
14. Cell-based high-throughput screening assay system for monitoring G protein-coupled receptor activation using beta-galactosidase enzyme complementation technology.
Yan YX; Boldt-Houle DM; Tillotson BP; Gee MA; D'Eon BJ; Chang XJ; Olesen CE; Palmer MA
J Biomol Screen; 2002 Oct; 7(5):451-9. PubMed ID: 14599361
[TBL] [Abstract][Full Text] [Related]
15. Psoralenquinones as a novel class of proteasome inhibitors: design, synthesis and biological evaluation.
Marzaro G; Gandin V; Marzano C; Guiotto A; Chilin A
ChemMedChem; 2011 Jun; 6(6):996-1000. PubMed ID: 21472862
[No Abstract] [Full Text] [Related]
16. Proteasome inhibitors in multiple myeloma.
Anderson KC
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
[TBL] [Abstract][Full Text] [Related]
19. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
20. Identification of iNOS inhibitors using InteraX.
Mallinder PR; Wallace AV; Allenby G
J Biomol Screen; 2009 Mar; 14(3):263-72. PubMed ID: 19211775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
